The United States Food and Drug Administration (FDA) approved Tivicay, GlaxoSmithKline Plc's drug targeted at HIV-1, the most common strain of the virus that causes Aids.
The drug, known generically as dolutegravir, is intended to be taken daily in combination with other HIV drugs
To read the full, original article click on this link: US FDA approves GSK's HIV-1 drug
